Regulation of p53 level by UBE4B in breast cancer

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Zhang, Ying ^a   Lv, Yanrong ^a   Zhang, Yongyang ^b   Gao, Haidong ^a  

^a SHANDONG UNIVERSITY   (China)

^b First People's Hospital of Jining   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LIGASE; PROTEIN P53; PROTEIN UBE4B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; TUMOR PROMOTION; UBIQUITINATION;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CARCINOGENESIS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASE COMPLEXES; UBIQUITINATION;

EID: 84896385598     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090154     Document Type: Article

References (23)

1. Hershko A, Ciechanover A (1999) The ubiquitin system. Annu Rev Biochem 67: 425-79. (Pubitemid 28411135)
2. Haglund K, Dikic I (2005) Ubiquitylation and cell signaling. EMBO J 24(19): 3353-9. (Pubitemid 41486773)
3. Pickart CM, Cohen RE (2004) Proteasomes and their kin: proteases in the machine age. Nat Rev Mol Cell Biol 5(3): 177-87. (Pubitemid 38325799)
4. Johnson ES, Ma PC, Ota IM, Varshavsky A (1995) A proteolytic pathway that recognizes ubiquitin as a degradation signal. J Biol Chem 270(29): 17442-56.
5. Koegl M, Hoppe T, Schlenker S, Ulrich HD, Mayer TU, et al (1999) A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 96(5): 635-44. (Pubitemid 29122806)
6. Hatakeyama S, Yada M, Matsumoto M, Ishida N, Nakayama KI (2001) U box proteins as a new family of ubiquitin-protein ligases. J Biol Chem 276(35): 33111-20.
7. Wu H, Pomeroy SL, Ferreira M, Teider N, Mariani J, et al (2011) UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53. Nat Med 17(3): 347-55. doi: 10.1038/nm.2283.
8. Wu H, Leng RP (2011) UBE4B, a ubiquitin chain assembly factor, is required for MDM2-mediated p53 polyubiquitination and degradation. Cell Cycle 10(12): 1912-5.
9. Lane DP, Crawford LV (1979) T antigen is bound to a host protein in SV40-transformed cells. Nature 278(5701): 261-3. (Pubitemid 9129076)
10. DeLeo AB, Jay G, Appella E, Dubois GC, Law LW, et al (1979) Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A 76(5): 2420-4. (Pubitemid 9185501)
11. Linzer DI, Levine AJ (1979) Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17(1): 43-52. (Pubitemid 9188209)
12. Lacroix M, Toillon RA, Leclercq G (2006) p53 and breast cancer, an update. Endocr Relat Cancer 13(2): 293-325. (Pubitemid 43886660)
13. Manic S, Gatti L, Carenini N, Fumagalli G, Zunino F, et al (2003) Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr Cancer Drug Targets 3(1): 21-9. (Pubitemid 36119418)
14. Ginsburg OM, Love RR (2011) Breast cancer: a neglected disease for the majority of affected women worldwide. Breast J 17(3): 289-95. doi: 10.1111/j.1524-4741.2011.01067.x.
15. Jerry DJ, Dunphy KA, Hagen MJ (2010) Estrogens, regulation of p53 and breast cancer risk: a balancing act. Cell Mol Life Sci 67(7): 1017-23.
16. Momand J, Jung D, Wilczynski S, Niland J (1998) The MDM2 gene amplification database. Nucleic Acids Res 26(15): 3453-9. (Pubitemid 28347214)
17. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, et al (2006) MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner. Cancer Res 66(10): 5104-10. (Pubitemid 43844932)
18. Sheikh MS, Shao ZM, Hussain A, Fontana JA (1993)The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res 53(14): 3226-8. (Pubitemid 23223285)
19. Bhatt P, d'Avout C, Kane NS, Borowiec JA, Saxena A (2012) Specific domains of nucleolin interact with Hdm2 and antagonize Hdm2-mediated p53-ubiquitination. FEBS J 279(3): 370-83. doi: 10.1111/j.1742-4658.2011.08430. x.
20. Lai Z, Ferry KV, Diamond MA, Wee KE, Kim YB, et al (2001) Human mdm2 mediates multiple mono-ubiquitination of p53 by a mechanism requiring enzyme is omerization. J Biol Chem 276(33): 31357-67. (Pubitemid 37385007)
21. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, et al (2003) Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 302(5652): 1972-5. (Pubitemid 37523506)
22. Matsumoto M, Yada M, Hatakeyama S, Ishimoto H, Tanimura T, et al (2004) Molecular clearance of ataxin-3 is regulated by a mammalian E4. EMBO J 23(3): 659-69. (Pubitemid 38282397)
23. Zage PE, Sirisaengtaksin N, Liu Y, Gireud M, Brown BS, et al (2013) UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors. Cancer 119(4): 915-23. doi: 10.1002/cncr.27785.